EFFECTS OF STRONTIUM RANELATE ON ALVEOLAR BONE IN RATS WITH EXPERIMENTAL DIABETES MELLITUS

Abstract

OBJECTIVE: The aim: To investigate effects of strontium ranelate on alveolar bone loss in rats with experimental diabetes. PATIENTS AND METHODS: Materials and methods: Histological examination of bone tissue was carried out for 24 white male rats, divided into three identical groups of 8 animals (the first group included animals with experimental type-2 diabetes, based on the use of Streptozotocin; in the second group, it was additionally reproduced periodontitis by the introduction of Penicillamine; and in the third group, in addition, it was used strontium ranelate) and 6 intact rats. RESULTS: Results: In the second group, osteoporosis phenomena were most significant, while in the third group the average specific area of the inter-root trabecular bone differed a little from the control. In the control group, the number of osteoclasts was 2.24 ± 1.41 cells per mm2, in the first group - 4.34 ± 1.37 cells per mm2, in the second group - 2.96 ± 1.26 cells per mm2 and in the third group - 2.24 ± 1.41 cells per mm2 (p>0.05). The samples of the third group have the most expressive manifestations of osteogenesis and the most intense expression of osteopontin, both in trabecular and compact bone tissue. CONCLUSION: Conclusions: The use of strontium drugs reliably slows down the processes of bone resorption due to both inhibition of the function of osteoclasts, and by activating osteoblasts, thus stimulating osteogenesis.